drugset / Trial / NCT00126139
Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis
Phase 3
Terminated
100 enrolled
University of Zurich
Eli Lilly and Company · collabSchweizerische Herzstiftung · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
The purpose of the present prospective, randomized, double-blind, double dummy controlled multicenter pilot study is to investigate whether abciximab, compared with aspirin, is able to reduce the rate of recurrent ischemic strokes before and during carotid endarterectomy \[CEA\] (primary endpoints); and the degree of carotid stenosis, number of microembolic signal (MES) counts, number of ischemic infarcts at diffusion weighted imaging (DWI) and amount of intraluminal thrombus at pathological examination (secondary endpoints) in patients with ischemic stroke due to a \>50% carotid stenosis who will undergo CEA.
Timeline
- Start
- 2004-04
- Primary completion
- —
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abciximab | Monoclonal antibody | — | — |